|
1
|
Yersal O and Barutca S: Biological
subtypes of breast cancer: Prognostic and therapeutic implications.
World J Clin Oncol. 10:412–424. 2014. View Article : Google Scholar
|
|
2
|
Brierley JD, Gospodarowicz MK and
Wittekind C: TNM Classification of Malignant Tumours. 8th. Oxford;
UK: Wiley Blackwell: 2017
|
|
3
|
Senkus E, Kyriakides S, Ohno S,
Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S and Cardoso
F; ESMO Guidelines Committee, : Primary breast cancer: ESMO
clinical practice guidelines. Ann Oncol. 26 (Suppl 5):v8–v30. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nadji M, Gomez-Fernandez C, Ganjei-Azar P
and Morales AR: Immuno-histochemistry of estrogen and progesterone
receptors reconsidered: Experience with 5,993 breast cancers. Am J
Clin Pathol. 123:21–27. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ragab HM, Samy N, Afify M, Maksoud NA and
Shaaban HM: Assessment of Ki-67 as a potential biomarker in
patients with breast cancer. J Genet Engineering and Biotechnol.
16:479–484. 2018. View Article : Google Scholar
|
|
6
|
Gnant M, Thomssen C and Harbeck N: St.
Gallen/Vienna 2015: A Brief summary of the consensus discussion.
Breast Care (Basel). 10:124–130. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carey LA, Perou CM, Livasy CA, Dressler
LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S,
et al: Race, breast cancer subtypes, and survival in the Carolina
breast cancer study. JAMA. 295:2492–24502. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Creighton CJ: The molecular profile of
luminal B breast cancer. Biologics. 6:289–297. 2012.PubMed/NCBI
|
|
9
|
Hubalek M, Czech T and Müller H:
Biological subtypes of triple-negative breast cancer. Breast Care
(Basel). 12:8–14. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Godet I and Gilkes DM: BRCA1 and BRCA2
mutations and treatment strategies for breast cancer. Integr Cancer
Sci Ther. 4:2017.PubMed/NCBI
|
|
11
|
Apostolou P and Papasotiriou I: Current
perspectives on CHEK2 mutations in breast cancer. Breast Cancer
(Dove Med Press). 9:331–335. 2017.PubMed/NCBI
|
|
12
|
Silwal-Pandit L, Vollan HK, Chin SF, Rueda
OM, McKinney S, Osako T, Quigley DA, Kristensen VN, Aparicio S,
Børresen-Dale AL, et al: TP53 mutation spectrum in breast cancer is
subtype specific and has distinct prognostic relevance. Clin Cancer
Res. 20:3570–3580. 2014. View Article : Google Scholar
|
|
13
|
Southey MC, Winship I and Nguyen-Dumont T:
PALB2: Research reaching to clinical outcomes for women with breast
cancer. Hered Cancer Clin Pract. 14:92016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huszno J, Nożyńska EZ, Lange D, Kołosza Z
and Nowara E: The association of tumor lymphocyte infiltration with
clinicopathological factors and survival in breast cancer. Pol J
Pathol. 68:26–32. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Montagna E, Vingiani A, Maisonneuve P,
Cancello G, Contaldo F, Pruneri G and Colleoni M: Unfavorable
prognostic role of tumor-infiltrating lymphocytes in
hormone-receptor positive, HER2 negative metastatic breast cancer
treated with metronomic chemotherapy. Breast. 34:83–88. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huszno J, Kołosza Z and Grzybowska E:
BRCA1 mutation in breast cancer patients: Analysis of prognostic
factors and survival. Oncol Lett. 17:1986–1995. 2019.PubMed/NCBI
|
|
17
|
Huszno J, Budryk M, Kołosza Z, Tęcza K,
Pamuła Piłat J, Nowara E and Grzybowska E: A comparison between
CHEK2*1100delC/I157T mutation carrier and noncarrier breast cancer
patients: A clinicopathological analysis. Oncology. 90:193–198.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huszno J, Kołosza K, Tęcza T, Pamuła-Piłat
J, Mazur M and Grzybowska E: Comparison between NOD2 gene
mutation carriers (3020insC) and non-carriers in breast cancer
patients: A clinicopathological and survival analysis. AMS
Civilization Dis. 3:10e–15e. 2018. View Article : Google Scholar
|
|
19
|
Triantafyllidou O, Vlachos IS, Apostolou
P, Konstantopoulou I, Grivas A, Panopoulos C, Dimitrakakis C,
Kassanos D, Loghis C, Bramis I, et al: Epidemiological and
clinicopathological characteristics of BRCA-positive and
BRCA-negative breast cancer patients in Greece. J BUON.
20:978–984. 2015.PubMed/NCBI
|
|
20
|
Kutomi G, Ohmura T, Suzuki Y, Kameshima H,
Shima H, Takamaru T, Satomi F, Otokozawa S, Mori M and Hirata K:
Clinicopathological characteristics of basal type breast cancer in
triple-negative breast cancer. J Cancer Therapy. 3:836–840. 2012.
View Article : Google Scholar
|
|
21
|
Evans DG, Lalloo F, Howell S, Verhoef S,
Woodward ER and Howell A: Low prevalence of HER2 positivity amongst
BRCA1 and BRCA2 mutation carriers and in primary BRCA screens.
Breast Cancer Res Treat. 155:597–601. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Peshkin BN, Alabek ML and Isaacs C:
BRCA1/2 mutations and triple negative breast cancers. Breast Dis.
32:25–33. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huszno J, Budryk M, Kołosza Z and Nowara
E: The influence of BRCA1/BRCA2 mutations on toxicity related to
chemotherapy and radiotherapy in early breast cancer patients.
Oncology. 85:278–82. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kirova YM, Savignoni A, Sigal-Zafrani B,
de La Rochefordiere A, Salmon RJ, This P, Asselain B,
Stoppa-Lyonnet D and Fourquet A: Is the breast conserving treatment
with radiotherapy appropriate in BRCA1/2 mutation carries?
Long-term results and review of the literature. Breast Cancer Res
Treat. 120:119–126. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
de Bock GH, Mourits MJ, Schutte M,
Krol-Warmerdam EM, Seynaeve C, Blom J, Brekelmans CT,
Meijers-Heijboer H, van Asperen CJ, Cornelisse CJ, et al:
Association between the CHEK2*1100delC germ line mutation and
estrogen receptor status. Int J Gynecol Cancer. 16:552–555. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cybulski C, Huzarski T, Byrski T, Gronwald
J, Debniak T, Jakubowska A, Gorski B, Wokolorczyk D, Masojc B,
Narod SA and Lubiński J: Estrogen receptor status in CHEK2-positive
breast cancers: Implications for chemoprevention. Clin Genet.
75:72–78. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kilpivaara O, Bartkova J, Eerola H,
Syrjäkoski K, Vahteristo P, Lukas J, Blomqvist C, Holli K, Heikkilä
P, Sauter G, et al: Correlation of CHEK2 protein expression and
c.1100delC mutation status with tumor characteristics among
unselected breast cancer patients. Int J Cancer. 113:575–580. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Broeks A, Braaf LM, Huseinovic A, Nooijen
A, Urbanus J, Hogervorst FB, Schmidt MK, Klijn JG, Russell NS, Van
Leeuwen FE and Van't Veer LJ: Identification of women with an
increased risk of developing radiation-induced breast cancer: A
case only study. Breast Cancer Res. 9:R262007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Domagala D, Wokolorczyk D, Cybulski C,
Huzarski T, Lubinski J and Domagala W: Different CHEK2 germline
mutation are associated with distinct immunophenotyping molecular
subtypes of breast cancer. Breast Cancer Res Treat. 132:937–945.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huzarski T, Lener M, Domagala W, Gronwald
J, Byrski T, Kurzawski G, Suchy J, Chosia M, Woyton J, Ucinski M,
et al: The 3020insC allele of NOD2 predisposes to early-onset
breast cancer. Breast Cancer Res Treat. 89:91–93. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Janiszewska H, Haus O, Lauda-Swieciak A,
Bak A, Mierzwa T, Sir J and Laskowski R: The NOD2 3020insC mutation
in women with breast cancer from the Bydgoszcz region in Poland.
First results. Hered Cancer Clin Pract. 4:15–19. 2006. View Article : Google Scholar : PubMed/NCBI
|
